Professor Caroline Moore studied at St George’s Hospital Medical School in Tooting, London and did post-graduate training in London and Surrey. She was a Royal College of Surgeons research fellow in 2002, working on photodynamic therapy for prostate cancer. She has pursued a clinical academic career since then, developing a portfolio of trials in a number of aspects of prostate cancer diagnosis and management. She has funding awards from the Medical Research Council, Cancer Research UK, Prostate Cancer UK, Movember, the National Institute for Health Research, the European Association of Urology Research Foundation, the Wellcome Trust and the Department of Health.

Caroline has been an honorary consultant urologist at University College Hospitals Trust since 2012, and Professor of Urology at University College London since 2018.

Her clinical work focuses on the detection, surveillance and minimally invasive treatment of prostate cancer, using an MRI-led approach. Caroline is committed to individualised prostate cancer assessment and treatment, combining imaging with shared decision making for men with localised prostate cancer.

Her research interests include using patient reported outcomes to identify and disseminate best surgical practice; the use of MRI and different approaches to psychological support for men on active surveillance; decision making in localised prostate cancer; and the development of non-traditional follow up methods after prostate cancer diagnosis.

Caroline leads the UCLH team for prostate cancer diagnosis, active surveillance and focal therapy. The team has won numerous awards for their work, including the BMJ Research Paper of the Year in 2019. They have delivered the highest number of focal treatments for prostate cancer, and have recently published outcomes for over 1000 men having focal HIFU as a first treatment for prostate cancer. She led the START international working groups on the use of MRI to detect prostate cancer, which led to the PRECISION study, for which she was. Chief Investigator. PRECISION showed that MRI is better at detecting cancers which need treating, whilst allowing 1 in 3 men to avoid biopsy and reducing overdiagnosis by half. She is working with Professor Mark Emberton on an MRC funded study (Re-Imagine Prostate Cancer screening) using MRI to screen for prostate cancer.

Areas of Urological Practice

Detection, surveillance and minimally invasive treatment of prostate cancer 

References

Google scholar

Key references

MRI to detect prostate cancer

RI-Targeted or Standard Biopsy for Prostate-Cancer Diagnosis. Kasivisvanathan V, Rannikko AS, Borghi M, Panebianco V, Mynderse LA, Vaarala MH, Briganti A, Budäus L, Hellawell G, Hindley RG, Roobol MJ, Eggener S, Ghei M, Villers A, Bladou F, Villeirs GM, Virdi J, Boxler S, Robert G, Singh PB,Venderink W, Hadaschik BA, Ruffion A, Hu JC, Margolis D, Crouzet S, Klotz L,Taneja SS, Pinto P, Gill I, Allen C, Giganti F, Freeman A, Morris S, Punwani S,Williams NR, Brew-Graves C, Deeks J, Takwoingi Y, Emberton M, Moore CM; PRECISION Study Group Collaborators. N Engl J Med. 2018 May 10;378(19):1767-1777. doi:10.1056/NEJMoa1801993. Epub 2018 Mar 18. PubMed PMID: 29552975.

Magnetic Resonance Imaging-targeted Biopsy Versus Systematic Biopsy in the Detection of Prostate Cancer: A Systematic Review and Meta-analysis. Kasivisvanathan V, Stabile A, Neves JB, Giganti F, Valerio M, Shanmugabavan Y, Clement KD, Sarkar D, Philippou Y, Thurtle D, Deeks J, Emberton M, Takwoingi Y, Moore CM. Eur Urol. 2019 May 23. pii: S0302-2838(19)30360-4. doi: 10.1016/j.eururo.2019.04.043. [Epub ahead of print] Review. PubMed PMID: 31130434.

Standards of reporting for MRI-targeted biopsy studies (START) of the prostate: Recommendations from an international working group.Moore, C.M., Kasivisvanathan, V., Eggener, S., Emberton, M., Fütterer, J.J., Gill, I.S., …Margolis, D.J.A. (2013). European Urology, 64 (4), 544-552. doi:10.1016/j.eururo.2013.03.030 Giganti F, Rosenkrantz AB, Villeirs G, Panebianco V, Stabile A, Emberton M, Moore CM. The Evolution of MRI of the Prostate: The Past, the Present, and the Future. AJR Am J Roentgenol. 2019 Apr 30:1-13. doi: 10.2214/AJR.18.20796. [Epub ahead of print] PubMed PMID: 31039022.

MRI-based volumetric analysis and oncological outcome. Giganti F, Stabile A, Giona S, Marenco J, Orczyk C, Moore CM, Allen C, Kirkham A, Emberton M, Punwani S. Prostate cancer treated with irreversible electroporation: Magn Reson Imaging. 2019 May;58:143-147. doi: 10.1016/j.mri.2019.02.003. Epub 2019 Feb 12. PubMed PMID: 30768957.

Medium-term oncological outcomes in a large cohort of men treated with either focal or hemi-ablation using high-intensity focused ultrasonography for primary localized prostate cancer. Stabile A, Orczyk C, Hosking-Jervis F, Giganti F, Arya M, Hindley RG,Dickinson L, Allen C, Punwani S, Jameson C, Freeman A, McCartan N, Montorsi F, Briganti A, Ahmed HU, Emberton M, Moore CM. BJU Int. 2019 Feb 12. doi: 10.1111/bju.14710. [Epub ahead of print] PubMed PMID:30753756.

MRI in active surveillance

  • Moore, C.M., Giganti, F., Albertsen, P., Allen, C., Bangma, C., Briganti, A., …Kirkham, A. (2017). Reporting Magnetic Resonance Imaging in Men on Active Surveillance for Prostate Cancer: The PRECISE Recommendations-A Report of a European School of Oncology Task Force. EUROPEAN UROLOGY, 71 (4), 648-655. doi:10.1016/j.eururo.2016.06.011
  • Giganti, F., Moore, C. M., Robertson, N. L., Emberton, M., & Kirkham, A. (2017). MRI findings in men on active surveillance for prostate cancer: does dutasteride make MRI visible lesions less conspicuous? Results from a pilot randomised controlled trial.. European Radiology. 10.1007/s00330-017-4858-0
  • Moore, C.M., Robertson, N.L., Jichi, F., Damola, A., Ambler, G., Giganti, F., …Ahmed, H.U. (2017). The Effect of Dutasteride on Magnetic Resonance Imaging Defined Prostate Cancer: MAPPED-A Randomized, Placebo Controlled, Double-Blind Clinical Trial. JOURNAL OF UROLOGY, 197 (4), 1006-1013. doi:10.1016/j.juro.2016.11.090
  • Schoots, I.G., Petrides, N., Giganti, F., Bokhorst, L.P., Rannikko, A., Klotz, L., …Moore, C.M. (2015). Magnetic resonance imaging in active surveillance of prostate cancer: a systematic review. EUROPEAN UROLOGY, 67 (4), 627-636. doi:10.1016/j.eururo.2014.10.050
  • Dieffenbacher S, Nyarangi-Dix J, Giganti F, Bonekamp D, Kesch C, Müller-Wolf MB, Schütz V, Gasch C, Hatiboglu G, Hauffe M, Stenzinger A, Duensing S, Schlemmer HP, Moore CM, Hohenfellner M, Radtke JP. Standardized Magnetic Resonance Imaging Reporting Using the Prostate Cancer Radiological Estimation of Change in Sequential Evaluation Criteria and Magnetic Resonance Imaging/Transrectal Ultrasound Fusion with Transperineal Saturation Biopsy to Select Men on Active Surveillance. Eur Urol Focus. 2019 Mar 13. pii: S2405-4569(19)30076-8. doi: 10.1016/j.euf.2019.03.001. [Epub ahead of print] PubMed PMID: 30878348.
  • Giganti F, Allen C, Piper JW, Mirando D, Stabile A, Punwani S, Kirkham A, Emberton M, Moore CM. Sequential prostate MRI reporting in men on active surveillance: initial experience of a dedicated PRECISE software program. Magn Reson Imaging. 2019 Apr;57:34-39. doi: 10.1016/j.mri.2018.10.013. Epub 2018 Oct 20. PubMed PMID: 30352271.
  • Merriel SWD, Hetherington L, Seggie A, Castle JT, Cross W, Roobol MJ, Gnanapragasam V, Moore CM; Prostate Cancer UK Expert Reference Group on Active Surveillance. Best practice in active surveillance for men with prostate cancer: a Prostate Cancer UK consensus statement. BJU Int. 2019 Jul;124(1):47-54. doi: 10.1111/bju.14707. Epub 2019 Mar 7. PubMed PMID: 30742733.